Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PaloBiofarma

Request full access

A company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation

Noáin (Valle de Elorz)/Noain (Elortzibar), SpainFounded 2006Biotech & Life Sciences

About PaloBiofarma

Developer of drugs intended to cure diseases based on the modulation of adenosine receptors. The company focuses to discover the first marketed drug based on a selective adenosine receptor modulator leveraging medicinal chemistry and in vitro pharmacology of adenosine, enabling doctors to focus on the treatment of advanced prostate cancer.

Source: Dealroom company data

PaloBiofarma in the Noáin (Valle de Elorz)/Noain (Elortzibar) ecosystem

Live from Dealroom

The PaloBiofarma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Inveready
  • Fitalent
  • European Innovation Council

Series A2 investors entered at this stage

  • Sodena
  • Foundation for Prader-Willi Syndrome Research

Series B and later1 investor entered at this stage

  • Asabys Partners
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See PaloBiofarma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.